Core Insights - enVVeno Medical Corporation reported its financial results for the year ended December 31, 2025, highlighting the strategic advancement of its enVVe® System and the completion of pre-clinical studies, with plans to initiate a pivotal trial in 2026 [2][3] Financial Performance - The company reported a net loss of $19.5 million for 2025, an improvement from a net loss of $21.8 million in 2024 [5] - Research and development expenses decreased by 19% year-over-year to $10.0 million, while selling, general, and administrative expenses were $10.9 million [5] - As of December 31, 2025, the company held $28.2 million in cash and investments, with an expected cash burn rate of approximately $4 million to $5 million per quarter in 2026 [5] Product Development - The enVVe System is a first-in-class, non-surgical, transcatheter-based replacement venous valve aimed at treating severe chronic venous insufficiency (CVI) by restoring proper blood flow in leg veins [4] - The system is designed to eliminate the need for open surgery, reduce procedural risks, and improve patient quality of life, addressing a significant unmet medical need in the treatment of CVI [4][3] - Chronic venous disease affects an estimated 70% of the adult population in the U.S., with severe CVI impacting approximately 3.5 million patients, including 1.5 million with venous leg ulcers [3]

Financial Performance - The company reported net losses of $19.5 million for the year ended December 31, 2025, a decrease of 11% from a net loss of $21.8 million in 2024[177]. - The company incurred losses from operations of $20.9 million and used $15.6 million in cash for operating activities in 2025, a decrease from $16.8 million in 2024[182]. Expenses - Research and development expenses decreased by $2.2 million or 19%, to $10.0 million in 2025 from $12.2 million in 2024, primarily due to lower costs related to the VenoValve study[179]. - Selling, general and administrative expenses decreased by $0.7 million or 6%, to $10.9 million in 2025 from $11.6 million in 2024, driven by non-recurring legal costs incurred in 2024[180]. Cash Position - The cash balance as of December 31, 2025, was $3.1 million, with total cash and investments amounting to $28.2 million[182]. - The company anticipates an increase in cash burn rate to between $4 million and $5 million per quarter in 2026, while having sufficient cash to fund operations through mid-2027[185]. Product Development - The enVVe System, a next-generation non-surgical venous valve product, has completed pre-clinical testing and discussions with the FDA regarding the pivotal trial are expected to begin in 2026[173]. - The company is focused on obtaining FDA approval for the enVVe System, with no current devices approved for surgical or non-surgical replacement venous valves[172]. - The company will continue to incur costs related to clinical trials for the VenoValve and enVVe System as it seeks regulatory approval for its product candidates[183]. Corporate Actions - A reverse stock split of one-for-thirty-five (1:35) was approved and became effective on January 20, 2026[175].

Core Viewpoint - NorthStrive Fund II LP, owning approximately 5.05% of enVVeno Medical Corporation, is advocating for a change in the company's strategic direction, including a call for a Special Meeting of Shareholders to discuss alternatives to the current plan [1][3][14]. Financial Position - As of September 30, 2025, enVVeno reported approximately $28 million in cash and short-term investments, with no long-term debt, and an annualized cash burn rate of about $16 million, indicating a cash runway of approximately 20-21 months [4]. - The company’s balance sheet is viewed as its primary asset, with an estimated $28.5 million potentially available for distribution after satisfying liabilities in a liquidation scenario [9]. Strategic Recommendations - NorthStrive Fund II suggests halting non-essential clinical expenditures to preserve capital and pursuing either an orderly liquidation or a strategic merger/reverse merger to maximize shareholder value [5][12][16]. - The estimated proceeds from a full liquidation scenario could be approximately $43.47 per share, representing around 335% upside for shareholders, which does not rely on future clinical success or external financing [10][11]. Board Engagement - NorthStrive Fund II has expressed disagreement with the Board's decision not to pursue their recommendations and is formally requesting the Board to call a Special Meeting of Shareholders to allow for a vote on the company's strategic direction [2][3][14]. - The Board collectively owns approximately 10,097 shares of Common Stock, representing less than 2% of the total outstanding shares, which raises concerns about their alignment with public shareholders' risks [8][9].

Financial Position - As of December 31, 2025, enVVeno Medical Corporation reported a cash and investments balance of approximately $28 million[4] Compliance and Listing - The company announced it regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Stock Market[5]

Core Viewpoint - enVVeno Medical Corporation has announced a reverse stock split of its common stock at a ratio of 1 for 35, effective at 12:01 a.m. on January 15, 2026 [1] Company Summary - The Board of Directors of enVVeno Medical Corporation has approved the reverse stock split [1]

Core Viewpoint - enVVeno Medical Corporation will host a Live Virtual Investor CEO Connect segment featuring CEO Robert Berman on December 3, 2025, at 4:00 PM ET [1] Company Information - enVVeno Medical Corporation is listed on Nasdaq under the ticker NVNO [1] - The event aims to connect investors with the company's leadership, providing insights into its operations and future prospects [1]

Group 1: RLX Technology Inc - RLX Technology Inc reported quarterly earnings of 3 cents per share on sales of $158.600 million [1] - Shares of RLX Technology rose 6% to $2.47 in pre-market trading following the earnings report [1] Group 2: Other Stocks in Pre-Market Trading - Cidara Therapeutics, Inc. surged 92% to $203.50 after a Schedule 13D Amendment revealed beneficial ownership of 3.37 million shares [4] - Binah Capital Group, Inc. gained 52.2% to $2.17 after posting stronger-than-expected third-quarter results [4] - Expion360 Inc. rose 42.4% to $1.81 following its third-quarter results [4] - Aspire Biopharma Holdings, Inc. surged 31.2% to $0.1380 in pre-market trading [4] - Invivyd, Inc. gained 28.8% to $2.28 after reporting better-than-expected third-quarter financial results [4] - Milestone Scientific Inc. surged 26.3% to $0.4801 after reporting better-than-expected third-quarter sales [4] - Lazydays Holdings, Inc. gained 23.3% to $1.85 after a previous surge [4] - Omeros Corp gained 12.5% to $7.08 following a narrower-than-expected quarterly loss [4] - Nouveau Monde Graphite Inc rose 10% to $3.25 after a decline the previous day [4] Group 3: Declining Stocks in Pre-Market Trading - TSS Inc tumbled 40.2% to $9.10 after reporting a year-over-year decrease in third-quarter results [4] - enVVeno Medical Corp declined 35.8% to $0.42 after an unfavorable FDA appeal decision [4] - Nuvve Holding Corp fell 29.3% to $0.34 after announcing third-quarter results [4] - ESS Tech Inc shares dipped 24.2% to $3.22 after reporting weak quarterly sales [4] - Direct Digital Holdings Inc fell 18.8% to $0.23 after a significant gain the previous day [4] - StubHub Holdings Inc fell 18.8% to $15.28 after worse-than-expected third-quarter EPS results [4] - Mangoceuticals Inc dipped 17.7% to $0.98 after a decline the previous day [4] - Red Cat Holdings Inc dipped 15.1% to $6.57 after worse-than-expected financial results and a lowered FY25 sales guidance [4] - WhiteFiber Inc fell 13.4% to $17.21 after reporting worse-than-expected financial results [4] - Sobr Safe Inc fell 12.4% to $2.21 after a decline the previous day [4]

Core Viewpoint - enVVeno Medical Corporation has received an unfavorable decision from the FDA regarding its VenoValve® application, which indicates that the product does not meet the necessary safety and effectiveness standards [1] Company Summary - enVVeno Medical Corporation focuses on developing treatments for deep venous disease [1] - The company aimed to gain Premarket Approval (PMA) for its VenoValve®, a surgical replacement venous valve designed for severe deep chronic venous insufficiency (CVI) [1] Regulatory Summary - The FDA issued a not-approvable letter on August 19, 2025, which was upheld in a supervisory appeal [1] - The decision indicates that the VenoValve® failed to provide reasonable assurance of safety and effectiveness [1]

Core Insights - The company has sufficient cash and investments to fund current operations through Q2 2027, excluding VenoValve commercialization and the enVVe IDE study [1] - The cash burn for Q3 2025 was $4.2 million, which aligns with the projected quarterly range [1] - The company is engaged in an ongoing appeal with the FDA regarding the VenoValve PMA decision, with feedback anticipated by the end of 2025 [1] Financial Summary - The company ended Q3 2025 with $31.0 million in cash and investments [1]

Product Development - enVVeno Medical Corporation is focused on developing innovative bioprosthetic solutions for Chronic Venous Disease (CVD), which affects approximately 70% of the adult population in the U.S.[43] - The lead product, VenoValve, is currently in post-enrollment follow-up of its U.S. pivotal study, with full enrollment of 75 patients achieved on September 1, 2023[53] - The VenoValve has been granted Breakthrough Device designation by the FDA, and the company estimates that 2.5 million people in the U.S. with severe deep venous CVD could be candidates for this device[52] - The VenoValve aims to reduce venous hypertension and improve symptoms of severe deep venous CVD, including the potential to heal recurring venous leg ulcers[52] - The company is also developing a second product, enVVe, a non-surgical replacement venous valve, currently in pre-clinical testing[44] - The Company expects to file the IDE application for enVVe in the first quarter of 2026, pending resolution of regulatory issues with the VenoValve[65] Clinical Study Results - In the pivotal study, 85% of patients experienced a clinically meaningful benefit, with an average improvement of 7.91 points in the revised Venous Clinical Severity Score (rVCSS) at one year[55] Financial Performance - The Company reported net losses of $4.5 million for the three months ended September 30, 2025, a decrease of 20% from a net loss of $5.6 million in the same period of 2024[71] - The Company reported net losses of $15.7 million for the nine months ended September 30, 2025, compared to $15.6 million in the same period of 2024, representing a slight increase of 1%[77] - Research and development expenses decreased by 10% to $2.6 million for the three months ended September 30, 2025, down from $2.9 million in 2024, primarily due to lower costs related to the VenoValve pivotal study[73] - Selling, general and administrative expenses decreased by 31% to $2.3 million for the three months ended September 30, 2025, compared to $3.3 million in 2024[75] - Other income decreased by 35% to $0.3 million for the three months ended September 30, 2025, down from $0.5 million in 2024[76] - The Company finished 2024 with approximately $43.2 million in cash and investments, which decreased to approximately $31.0 million as of September 30, 2025[66] - The Company anticipates an increase in cash burn rate from approximately $4 million per quarter to between $5 million and $7 million per quarter as clinical trials progress[86] - The Company has sufficient capital resources to meet obligations for at least one year after the date of the Quarterly Report[87] Regulatory Matters - The company submitted the final module of its PMA application for the VenoValve to the FDA on November 19, 2024[56] - On August 19, 2025, the company received a not-approvable letter from the FDA regarding the VenoValve PMA application, citing insufficient data to determine the benefit-risk profile[58] - The company filed a request for supervisory appeal of the not-approvable letter on September 18, 2025, with a decision expected by the end of 2025[59] - The Company received a Nasdaq deficiency letter on October 7, 2025, due to the closing bid price of its common stock falling below $1.00 per share for 30 consecutive business days[67] Market Context - The average annual cost for a patient seeking treatment for a venous ulcer is approximately $30,000, with total direct medical costs exceeding $20 billion annually in the U.S.[51]